KMDA
Neutral signalScored 2026-09-20 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Kamada Ltd.
- Nom
- Kamada Ltd.
- Secteur
- Healthcare
- Industrie
- Drug Manufacturers - Specialty & Generic
- Bourse
- NASDAQ
- Capitalisation
- $460.4M
- Employés
- 462
- PDG
- Amir London
- Site web
- https://www.kamada.com
- Marché
- ADMAEBSPHAR
Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division. Its own manufactured portfolio includes KAMRAB/KEDRAB for rabies prevention, CYTOGAM to prevent cytomegalovirus disease in transplant recipients, WINRHO SDF for immune thrombocytopenic purpura and Rhesus (Rh) isoimmunization, HEPAGAM B for hepatitis B recurrence prevention following liver transplants and for post-exposure prophylaxis, VARIZIG for post-exposure chickenpox prophylaxis, and GLASSIA for intravenous alpha-1 antitrypsin deficiency (AATD). Kamada also produces KamRho (D) for the prophylaxis of hemolytic disease of newborns and immune thrombocytopenic purpura, along with a specific antiserum for Vipera palaestinae and Echis coloratus snake bites. Additionally, the company distributes a wide array of third-party pharmaceutical products, encompassing treatments like BRAMITOB for chronic pulmonary infections, FOSTER for asthma, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, and specialized therapies such as IVIG for immunodeficiency, VARITECT for chickenpox and zoster herpes, and various factors for hemophilia A and B, among numerous others for conditions like hepatitis B, cytomegalovirus, angioedema, Japanese encephalitis, and prostate cancer. Kamada markets its offerings in the United States through strategic partners and internationally via a network of distributors. The company maintains significant collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, Kamada Ltd. is headquartered in Rehovot, Israel.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 200 000 titres (~1 650 458,60 $ US)
- Insiders
- Tsur David
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$1,650,459
Avg sell (VWAP, 90d window) $8.25 vs last close $8.77 (+6.3%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-09-14
- Liquidity
- Thin $1,381,219/day · 20d vol
- Last synced
-
2026-09-23 21:10:39
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-14 | Tsur David | Sell · S | 22,827 | $8.18 | $186,725 | Form 4 |
| 2026-09-09 | Tsur David | Sell · S | 175 | $8.26 | $1,446 | Form 4 |
| 2026-09-08 | Tsur David | Sell · S | 162,760 | $8.26 | $1,344,398 | Form 4 |
| 2026-09-07 | Tsur David | Sell · S | 14,238 | $8.28 | $117,891 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-09-20 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
KMDA exhibits strong financial health with excellent liquidity (90) and solid fundamental momentum (85), underpinned by a clear profitability turnaround and a clean balance sheet.
The first sentence of the analysis written for KMDA on 2026-09-20 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Supports a bullish reading. Current ratio 4.07 · operating margin 15%
Suggested stop 8.24, nearest stored support minus 0.5 ATR(6.0% under the last close). Reward/risk to the next stored resistance is 0.21. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 42.3% | 43.5% | 38.9% | 36.1% | 29.3% | |
| Ebit Margin | 13.5% | 8.7% | 6.8% | -1.0% | -1.5% | |
| Ebitda Margin | 21.7% | 17.3% | 14.9% | 8.4% | 3.9% | |
| Operating Profit Margin | 14.5% | 12.5% | 7.1% | 3.5% | -0.7% | |
| Pretax Profit Margin | 13.0% | 8.3% | 5.9% | -1.7% | -1.8% | |
| Continuous Operations Profit Margin | 11.2% | 9.0% | 5.8% | -1.8% | -2.2% | |
| Net Profit Margin | 11.2% | 9.0% | 5.8% | -1.8% | -2.2% | |
| Bottom Line Profit Margin | 11.2% | 9.0% | 5.8% | -1.8% | -2.2% | |
| Current Ratio | 4.074 | 3.733 | 3.427 | 1.836 | 2.406 | |
| Quick Ratio | 2.282 | 2.137 | 1.643 | 0.878 | 1.077 | |
| Solvency Ratio | 0.320 | 0.251 | 0.178 | 0.067 | 0.024 | |
| Cash Ratio | 1.592 | 1.588 | 1.122 | 0.453 | 0.344 | |
| Price To Earnings Ratio | 18.579 | 24.360 | 36.000 | -77.413 | -132.129 | |
| Price To Earnings Growth Ratio | 0.357 | 0.518 | -0.084 | -19.276 | 1.181 | |
| Forward Price To Earnings Growth Ratio | 0.357 | 0.518 | -0.084 | -19.276 | 1.181 | |
| Price To Earnings Diluted Ratio | 19.081 | 24.360 | 40.800 | -77.413 | -132.129 | |
| Price To Earnings Diluted Growth Ratio | 0.398 | 0.365 | -0.105 | -19.276 | 1.178 | |
| Price To Book Ratio | 1.512 | 1.349 | 1.225 | 1.021 | 1.666 | |
| Price To Sales Ratio | 2.255 | 2.175 | 2.097 | 1.389 | 2.842 | |
| Price To Free Cash Flow Ratio | 24.033 | 9.500 | -194.686 | 7.246 | -22.583 | |
| Price To Operating Cash Flow Ratio | 14.750 | 7.356 | 69.257 | 6.287 | -32.135 | |
| Debt To Assets Ratio | 0.031 | 0.030 | 0.025 | 0.064 | 0.076 | |
| Debt To Equity Ratio | 0.043 | 0.043 | 0.036 | 0.117 | 0.138 | |
| Debt To Capital Ratio | 0.041 | 0.041 | 0.035 | 0.105 | 0.121 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.069 | 0.090 | |
| Financial Leverage Ratio | 1.407 | 1.435 | 1.454 | 1.831 | 1.802 | |
| Working Capital Turnover Ratio | 1.286 | 1.261 | 1.552 | 1.857 | 0.905 | |
| Operating Cash Flow Ratio | 0.582 | 0.964 | 0.087 | 0.378 | -0.170 | |
| Operating Cash Flow Sales Ratio | 0.153 | 0.296 | 0.030 | 0.221 | -0.088 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.614 | 0.774 | -0.356 | 0.868 | 1.423 | |
| Debt Service Coverage Ratio | 12.052 | 43.833 | 16.219 | 2.006 | 1.257 | |
| Interest Coverage Ratio | 30.362 | 30.380 | 7.753 | 4.958 | -2.459 | |
| Short Term Operating Cash Flow Coverage Ratio | 13.006 | 0.000 | 0.000 | 6.432 | -3.484 | |
| Operating Cash Flow Coverage Ratio | 2.386 | 4.302 | 0.489 | 1.388 | -0.376 | |
| Capital Expenditure Coverage Ratio | 2.589 | 4.431 | 0.738 | 7.554 | -2.364 | |
| Dividend Paid And Capex Coverage Ratio | 1.192 | 4.431 | 0.738 | 7.554 | -2.364 | |
| Dividend Payout Ratio | 0.618 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 8.741 | 10.169 | 11.890 | 15.361 | 74.960 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 42.3% | ▼-1.1% | ▲4.3% |
| Ebit Margin | 13.5% | ▲4.8% | ▲8.2% |
| Ebitda Margin | 21.8% | ▲4.5% | ▲8.5% |
| Operating Profit Margin | 14.5% | ▲2.1% | ▲7.2% |
| Pretax Profit Margin | 13.0% | ▲4.7% | ▲8.3% |
| Continuous Operations Profit Margin | 11.2% | ▲2.2% | ▲6.8% |
| Net Profit Margin | 11.2% | ▲2.2% | ▲6.8% |
| Bottom Line Profit Margin | 11.2% | ▲2.2% | ▲6.8% |
| Current Ratio | 4.074 | ▲0.341 | ▲0.979 |
| Quick Ratio | 2.282 | ▲0.145 | ▲0.678 |
| Solvency Ratio | 0.320 | ▲0.070 | ▲0.152 |
| Cash Ratio | 1.592 | ▲0.004 | ▲0.573 |
| Price To Earnings Ratio | 18.579 | ▼-5.781 | ▲44.700 |
| Price To Earnings Growth Ratio | 0.357 | ▼-0.160 | ▲3.818 |
| Forward Price To Earnings Growth Ratio | 0.357 | ▼-0.160 | ▲3.818 |
| Price To Earnings Diluted Ratio | 19.081 | ▼-5.279 | ▲44.141 |
| Price To Earnings Diluted Growth Ratio | 0.398 | ▲0.032 | ▲3.885 |
| Price To Book Ratio | 1.512 | ▲0.163 | ▲0.158 |
| Price To Sales Ratio | 2.255 | ▲0.080 | ▲0.103 |
| Price To Free Cash Flow Ratio | 24.033 | ▲14.534 | ▲59.331 |
| Price To Operating Cash Flow Ratio | 14.750 | ▲7.394 | ▲1.647 |
| Debt To Assets Ratio | 0.030 | ▲0.001 | ▼-0.015 |
| Debt To Equity Ratio | 0.043 | ▲0.000 | ▼-0.032 |
| Debt To Capital Ratio | 0.041 | ▲0.000 | ▼-0.027 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | ▼-0.032 |
| Financial Leverage Ratio | 1.407 | ▼-0.027 | ▼-0.179 |
| Working Capital Turnover Ratio | 1.286 | ▲0.025 | ▼-0.086 |
| Operating Cash Flow Ratio | 0.582 | ▼-0.382 | ▲0.214 |
| Operating Cash Flow Sales Ratio | 0.153 | ▼-0.143 | ▲0.031 |
| Free Cash Flow Operating Cash Flow Ratio | 0.614 | ▼-0.161 | ▼-0.051 |
| Debt Service Coverage Ratio | 12.052 | ▼-31.782 | ▼-3.022 |
| Interest Coverage Ratio | 30.362 | ▼-0.018 | ▲16.163 |
| Short Term Operating Cash Flow Coverage Ratio | 13.006 | ▲13.006 | ▲9.816 |
| Operating Cash Flow Coverage Ratio | 2.386 | ▼-1.916 | ▲0.748 |
| Capital Expenditure Coverage Ratio | 2.589 | ▼-1.843 | ▼-0.001 |
| Dividend Paid And Capex Coverage Ratio | 1.192 | ▼-3.239 | ▼-1.118 |
| Dividend Payout Ratio | 0.618 | ▲0.618 | ▲0.494 |
| Enterprise Value Multiple | 8.741 | ▼-1.429 | ▼-15.483 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $407.0M | $350.1M | $298.8M | $179.7M | $294.6M | |
| Enterprise value | $343.1M | $282.7M | $252.0M | $166.1M | $300.4M | |
| EV / Sales | 1.90x | 1.76x | 1.77x | 1.28x | 2.90x | |
| EV / Op. cash flow | 12.43x | 5.94x | 58.41x | 5.81x | -32.76x | |
| EV / Free cash flow | 20.26x | 7.67x | -164.19x | 6.70x | -23.02x | |
| EV / EBITDA | 8.74x | 10.17x | 11.89x | 15.36x | 74.96x | |
| Net debt / EBITDA | -1.63x | -2.42x | -2.21x | -1.26x | 1.44x | |
| Current ratio | 4.07x | 3.73x | 3.43x | 1.84x | 2.41x | |
| Income quality | 1.26x | 3.29x | 0.52x | -12.32x | 3.96x | |
| Graham number | $6 | $5 | $4 | — | — | |
| Graham net-net | $1 | $0 | $0 | -$1 | -$1 | |
| Tax burden | 86.1% | 108.5% | 98.3% | 102.7% | 118.3% | |
| Interest burden | 96.4% | 95.3% | 86.7% | 168.0% | 117.7% | |
| Working capital | $145.7M | $135.0M | $120.4M | $63.3M | $76.0M | |
| Invested capital | $322.4M | $313.0M | $296.3M | $239.0M | $259.0M | |
| Return on assets | 5.3% | 3.9% | 2.3% | -0.7% | -0.7% | |
| Operating ROA | 7.0% | 5.5% | 3.0% | 1.4% | -0.3% | |
| Return on tangible assets | 8.0% | 6.0% | 3.9% | -1.3% | -1.4% | |
| Return on equity | 7.5% | 5.6% | 3.4% | -1.3% | -1.3% | |
| Return on invested capital | 6.8% | 6.2% | 3.2% | 1.8% | -0.3% | |
| Return on capital employed | 7.9% | 6.2% | 3.3% | 1.8% | -0.3% | |
| Earnings yield | 5.0% | 4.1% | 2.8% | -1.3% | -0.8% | |
| Free cash flow yield | 4.2% | 10.5% | -0.5% | 13.8% | -4.4% | |
| Capex / Op. cash flow | 38.6% | 22.6% | 135.6% | 13.2% | -42.3% | |
| Capex / Depreciation | 66.0% | 77.8% | 46.0% | 31.1% | 66.5% | |
| Capex / Sales | 5.9% | 6.7% | 4.1% | 2.9% | 3.7% | |
| SG&A / Sales | 18.8% | 19.2% | 19.3% | 19.4% | 16.9% | |
| R&D / Sales | 7.2% | 9.4% | 9.8% | 10.2% | 11.0% | |
| Stock comp / Sales | 0.0% | 0.5% | 0.9% | 0.9% | 0.0% | |
| Intangibles / Total assets | 33.4% | 35.5% | 39.4% | 45.6% | 48.2% | |
| Days sales outstanding | 59d | 53d | 55d | 80d | 125d | |
| Days payables outstanding | 82d | 111d | 104d | 145d | 125d | |
| Operating cycle | 357d | 369d | 426d | 400d | 483d | |
| Cash conversion cycle | 275d | 258d | 322d | 255d | 358d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-17 CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand U.S. Centers for Disease Control and Prevention (CDC) Reports a Significant Year-Over-Year Increase in Nationwide Rabies Exposures and Rabies Immunoglobulin Utilization KedRAB is One of Only Two FDA-Approved Anti-Rabies Immunoglobulin Products in the U.S. Market Estimated at $200 Million Annually Kamada''s Manufacturing Capacity and Supply Availability Positioned to Support Increased Demand REHOVOT, Israel, and HOBOKEN, N.J., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.
- 2026-09-10 Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference REHOVOT, Israel, and HOBOKEN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that Amir London, Chief Executive Officer, will participate and present at the H.C. Wainwright 28th Annual Global Investment Conference, taking place at the Lotte New York Palace Hotel.
- 2026-09-03 Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders REHOVOT, Israel and HOBOKEN, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (the “Company”) (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, announced today that it has obtained a tax ruling (the “Ruling”) from the Israel Tax Authority (the “ITA”) with respect to the cash dividend of $0.17 (approximately NIS 0.51) per share on the Company''s ordinary shares (totaling approximately $9.8 million) announced on August 17, 2026 (the “Dividend”), expected to be paid on September 17, 2026 (the “Payment Date”), to shareholders of record at the close of business on August 27, 2026 (the “Record Date”).
- 2026-08-17 Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026 Dividend to be Paid Consistent with the Company''s Cash Dividend Policy Dividend to be Paid Consistent with the Company''s Cash Dividend Policy
- 2026-08-14 Is Kamada (KMDA) a Solid Growth Stock? 3 Reasons to Think "Yes" Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.
- 2026-08-14 KMDA or PRTA: Which Is the Better Value Stock Right Now? Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Prothena (PRTA). But which of these two companies is the best option for those looking for undervalued stocks?
- 2026-08-14 Wall Street Analysts Think Kamada (KMDA) Could Surge 79.06%: Read This Before Placing a Bet The consensus price target hints at a 79.1% upside potential for Kamada (KMDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 2026-08-12 Kamada Ltd. (KMDA) Q2 2026 Earnings Call Transcript Kamada Ltd. (KMDA) Q2 2026 Earnings Call Transcript
- 2026-08-12 Kamada (KMDA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates Although the revenue and EPS for Kamada (KMDA) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 2026-08-12 Kamada (KMDA) Q2 Earnings and Revenues Surpass Estimates Kamada (KMDA) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.13 per share a year ago.